130 related articles for article (PubMed ID: 19281726)
1. In vitro and in vivo pharmacokinetic characteristics of clazosentan, an intravenous endothelin receptor antagonist, in humans.
van Giersbergen PL; Treiber A; Dingemanse J
Int J Clin Pharmacol Ther; 2009 Mar; 47(3):169-77. PubMed ID: 19281726
[TBL] [Abstract][Full Text] [Related]
2. Tolerability, pharmacokinetics, and pharmacodynamics of clazosentan, a parenteral endothelin receptor antagonist.
van Giersbergen PL; Dingemanse J
Eur J Clin Pharmacol; 2007 Feb; 63(2):151-8. PubMed ID: 16636870
[TBL] [Abstract][Full Text] [Related]
3. Influence of severe renal impairment on the pharmacokinetics of clazosentan.
Bruderer S; Sasu B; Tsvitbaum N; Dingemanse J
J Clin Pharmacol; 2011 Mar; 51(3):413-21. PubMed ID: 20926750
[TBL] [Abstract][Full Text] [Related]
4. Influence of different degrees of liver impairment on the pharmacokinetics of clazosentan.
Bruderer S; Detishin V; Tsvitbaum N; Dingemanse J
Br J Clin Pharmacol; 2011 Jan; 71(1):52-60. PubMed ID: 21143501
[TBL] [Abstract][Full Text] [Related]
5. In vivo and in vitro disposition profile of tezosentan, an intravenous dual endothelin receptor antagonist, in humans.
Treiber A; Van Giersbergen PL; Dingemanse J
Xenobiotica; 2003 Apr; 33(4):399-414. PubMed ID: 12745875
[TBL] [Abstract][Full Text] [Related]
6. Influence of ethnic origin and sex on the pharmacokinetics of clazosentan.
van Giersbergen PL; Gunawardena KA; Dingemanse J
J Clin Pharmacol; 2007 Nov; 47(11):1374-80. PubMed ID: 17906281
[TBL] [Abstract][Full Text] [Related]
7. Effect of gender on the tolerability, safety and pharmacokinetics of clazosentan following long-term infusion.
van Giersbergen PL; Dingemanse J
Clin Drug Investig; 2007; 27(11):797-802. PubMed ID: 17914898
[TBL] [Abstract][Full Text] [Related]
8. Target-Mediated Population Pharmacokinetic Modeling of Endothelin Receptor Antagonists.
Volz AK; Dingemanse J; Krause A; Lehr T
Pharm Res; 2019 Dec; 37(1):2. PubMed ID: 31823033
[TBL] [Abstract][Full Text] [Related]
9. Preventive Effect of Clazosentan against Cerebral Vasospasm after Clipping Surgery for Aneurysmal Subarachnoid Hemorrhage in Japanese and Korean Patients.
Fujimura M; Joo JY; Kim JS; Hatta M; Yokoyama Y; Tominaga T
Cerebrovasc Dis; 2017; 44(1-2):59-67. PubMed ID: 28463833
[TBL] [Abstract][Full Text] [Related]
10. Influence of Rifampin-Mediated Organic Anion-Transporting Polypeptide 1B1/1B3 Inhibition on the Pharmacokinetics of Clazosentan.
Juif PE; Voors-Pette C; Ufer M; Dogterom P; Dingemanse J
Clin Transl Sci; 2019 Sep; 12(5):440-444. PubMed ID: 31004470
[TBL] [Abstract][Full Text] [Related]
11. Challenges in collecting pharmacokinetic and pharmacodynamic information in an intensive care setting: PK/PD modelling of clazosentan in patients with aneurysmal subarachnoid haemorrhage.
Zisowsky J; Fuseau E; Bruderer S; Krause A; Dingemanse J
Eur J Clin Pharmacol; 2014 Apr; 70(4):409-19. PubMed ID: 24458541
[TBL] [Abstract][Full Text] [Related]
12. Association Between Vomiting and QT Hysteresis: Data from a TQT Study with the Endothelin A Receptor Antagonist Clazosentan.
Juif PE; Dingemanse J; Voors-Pette C; Ufer M
AAPS J; 2020 Aug; 22(5):103. PubMed ID: 32748293
[TBL] [Abstract][Full Text] [Related]
13. PK/PD modeling of a clazosentan thorough QT study with hysteresis in concentration-QT and RR-QT.
Henrich A; Juif PE; Dingemanse J; Krause A
J Pharmacokinet Pharmacodyn; 2021 Apr; 48(2):213-224. PubMed ID: 33389549
[TBL] [Abstract][Full Text] [Related]
14. Clazosentan (AXV-034343), a selective endothelin A receptor antagonist, in the prevention of cerebral vasospasm following severe aneurysmal subarachnoid hemorrhage: results of a randomized, double-blind, placebo-controlled, multicenter phase IIa study.
Vajkoczy P; Meyer B; Weidauer S; Raabe A; Thome C; Ringel F; Breu V; Schmiedek P
J Neurosurg; 2005 Jul; 103(1):9-17. PubMed ID: 16121967
[TBL] [Abstract][Full Text] [Related]
15. Metabolism, excretion, and pharmacokinetics of rosuvastatin in healthy adult male volunteers.
Martin PD; Warwick MJ; Dane AL; Hill SJ; Giles PB; Phillips PJ; Lenz E
Clin Ther; 2003 Nov; 25(11):2822-35. PubMed ID: 14693307
[TBL] [Abstract][Full Text] [Related]
16. Clazosentan, a novel endothelin A antagonist, improves cerebral blood flow and behavior after traumatic brain injury.
Kreipke CW; Rafols JA; Reynolds CA; Schafer S; Marinica A; Bedford C; Fronczak M; Kuhn D; Armstead WM
Neurol Res; 2011 Mar; 33(2):208-13. PubMed ID: 21801597
[TBL] [Abstract][Full Text] [Related]
17. Clazosentan, an endothelin receptor antagonist, in patients with aneurysmal subarachnoid haemorrhage undergoing surgical clipping: a randomised, double-blind, placebo-controlled phase 3 trial (CONSCIOUS-2).
Macdonald RL; Higashida RT; Keller E; Mayer SA; Molyneux A; Raabe A; Vajkoczy P; Wanke I; Bach D; Frey A; Marr A; Roux S; Kassell N
Lancet Neurol; 2011 Jul; 10(7):618-25. PubMed ID: 21640651
[TBL] [Abstract][Full Text] [Related]
18. Clazosentan, an endothelin receptor antagonist, prevents early hypoperfusion during the acute phase of massive experimental subarachnoid hemorrhage: a laser Doppler flowmetry study in rats.
Schubert GA; Schilling L; Thomé C
J Neurosurg; 2008 Dec; 109(6):1134-40. PubMed ID: 19035733
[TBL] [Abstract][Full Text] [Related]
19. Effects of the selective endothelin A (ET(A)) receptor antagonist Clazosentan on cerebral perfusion and cerebral oxygenation following severe subarachnoid hemorrhage - preliminary results from a randomized clinical series.
Barth M; Capelle HH; Münch E; Thomé C; Fiedler F; Schmiedek P; Vajkoczy P
Acta Neurochir (Wien); 2007; 149(9):911-8; discussion 918. PubMed ID: 17700991
[TBL] [Abstract][Full Text] [Related]
20. Clazosentan: First Approval.
Lee A
Drugs; 2022 Apr; 82(6):697-702. PubMed ID: 35362854
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]